DK1135125T3 - Doseringsformer med reguleret frigivelse omfattende zolpidem eller et salt deraf - Google Patents

Doseringsformer med reguleret frigivelse omfattende zolpidem eller et salt deraf

Info

Publication number
DK1135125T3
DK1135125T3 DK99968394T DK99968394T DK1135125T3 DK 1135125 T3 DK1135125 T3 DK 1135125T3 DK 99968394 T DK99968394 T DK 99968394T DK 99968394 T DK99968394 T DK 99968394T DK 1135125 T3 DK1135125 T3 DK 1135125T3
Authority
DK
Denmark
Prior art keywords
zolpidem
salt
controlled
dosage forms
release dosage
Prior art date
Application number
DK99968394T
Other languages
Danish (da)
English (en)
Inventor
Gerard Alaux
Gareth Lewis
Frederic Andre
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1135125(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of DK1135125T3 publication Critical patent/DK1135125T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
DK99968394T 1998-12-04 1999-12-01 Doseringsformer med reguleret frigivelse omfattende zolpidem eller et salt deraf DK1135125T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98403037A EP1005863A1 (fr) 1998-12-04 1998-12-04 Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
PCT/EP1999/010454 WO2000033835A1 (fr) 1998-12-04 1999-12-01 Formes posologiques a liberation regulee contenant du zolpidem ou un sel de celui-ci

Publications (1)

Publication Number Publication Date
DK1135125T3 true DK1135125T3 (da) 2005-07-11

Family

ID=8235578

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968394T DK1135125T3 (da) 1998-12-04 1999-12-01 Doseringsformer med reguleret frigivelse omfattende zolpidem eller et salt deraf

Country Status (28)

Country Link
US (1) US6514531B1 (fr)
EP (2) EP1005863A1 (fr)
JP (2) JP4574857B2 (fr)
KR (2) KR101013272B1 (fr)
CN (1) CN1212838C (fr)
AR (1) AR021535A1 (fr)
AT (1) ATE290861T1 (fr)
AU (1) AU771902B2 (fr)
BR (1) BR9915939A (fr)
CA (1) CA2391983C (fr)
CO (1) CO5261492A1 (fr)
CZ (1) CZ20011969A3 (fr)
DE (1) DE69924283T8 (fr)
DK (1) DK1135125T3 (fr)
ES (1) ES2239479T3 (fr)
HK (1) HK1037319A1 (fr)
HU (1) HUP0201915A3 (fr)
IL (2) IL143146A0 (fr)
NO (1) NO20012668L (fr)
NZ (1) NZ511750A (fr)
PL (1) PL198396B1 (fr)
PT (1) PT1135125E (fr)
SI (1) SI1135125T1 (fr)
SK (1) SK7612001A3 (fr)
TR (1) TR200101588T2 (fr)
TW (1) TW565448B (fr)
WO (1) WO2000033835A1 (fr)
ZA (1) ZA200104169B (fr)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
EP1064937A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à liberation controllée comprenant un hypnotique à courte duree ou une des ses sels
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
AU5066101A (en) 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2002018303A2 (fr) 2000-08-29 2002-03-07 Ranbaxy Laboratories Limited Synthese du n,n-dimethyl-3-(4-methyl)benzoyl-propionamide, un intermediaire cle du zolpidem
AU2002320309B2 (en) * 2001-07-06 2007-07-12 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004029A1 (fr) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Procedes de preparation de compositions a liberation entretenue d'oxymorphone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
JP2005523876A (ja) * 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
EP1485344A1 (fr) 2002-03-28 2004-12-15 Synthon B.V. Besylate de venlafaxine
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
ES2286486T3 (es) * 2002-12-17 2007-12-01 ABBOTT GMBH & CO. KG Formulacion que comprende acido fenofibrico, una sal o un derivado fisiologicamente aceptables del mismo.
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US7989006B2 (en) * 2003-04-08 2011-08-02 American River Nutrition, Inc. Annatto extract compositions, including geranyl geraniols and methods of use
WO2004096137A2 (fr) * 2003-04-08 2004-11-11 Barrie Tan Compositions d'extrait de rocou contenant des geranylgeraniols et modes d'utilisation
US7375111B2 (en) 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1660496A1 (fr) * 2003-07-31 2006-05-31 Ranbaxy Laboratories Limited Procede pour la synthese de zolpidem
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
WO2005030166A1 (fr) * 2003-09-26 2005-04-07 Alza Corporation Baton poussoir orosr pour l'administration controlee d'agents actifs
EP1708684A2 (fr) 2003-09-26 2006-10-11 Alza Corporation Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
JP5179757B2 (ja) * 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
ES2337700T3 (es) 2004-02-18 2010-04-28 Sepracor, Inc. Terapia combinada de agonista de dopamina con sedantes para mejorar la calidad del sueño.
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
ES2624585T3 (es) * 2004-05-28 2017-07-17 Imaginot Pty Ltd. Sistema de suministro de compuesto terapéutico oral
WO2005123039A1 (fr) 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Formulations de prevention des abus
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006002836A1 (fr) * 2004-07-01 2006-01-12 Losan Pharma Gmbh Compositions effervescentes de somniferes
CN1993112A (zh) * 2004-07-29 2007-07-04 赛诺菲-安万特 用于具有高度pH依赖性溶解度的活性成分的控释的药物多层片剂
GB0423800D0 (en) 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
WO2006046527A1 (fr) * 2004-10-28 2006-05-04 Kowa Co., Ltd. Préparation pharmaceutique solide se dissolvant dans la cavité orale
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
NZ563979A (en) * 2005-05-25 2011-02-25 Transcept Pharmaceuticals Inc Solid compositions and methods for treating middle-of-the night insomnia
FR2887455B1 (fr) * 2005-06-28 2007-08-10 Sanofi Aventis Sa Formulation a liberation prolongee de principes actifs de medicaments
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
WO2007065559A1 (fr) * 2005-11-18 2007-06-14 Synthon B.V. Comprimés de zolpidem
EP2135603B1 (fr) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions et procédés pour augmenter la sensibilité à l'insuline
WO2007089318A2 (fr) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions et méthodes de réduction de la boulimie
EP3449928A1 (fr) * 2005-11-28 2019-03-06 Imaginot Pty Ltd. Système d'administration d'un composé thérapeutique oral
AR056633A1 (es) * 2005-12-07 2007-10-17 Gador Sa Composiciones farmaceuticas de agentes hipnoticos de accion corta en forma de liberacion modificada y los procedimientos para preparar dichas formulaciones
WO2007069061A2 (fr) * 2005-12-16 2007-06-21 Wockhardt Ltd Compositions a liberation controlee contenant du zolpidem
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
KR20070091960A (ko) * 2006-03-08 2007-09-12 주식회사종근당 졸피뎀 또는 그의 염을 포함하는 안전한 제어방출형 제제조성물
US20070231381A1 (en) * 2006-03-31 2007-10-04 Sherman Bernard C Controlled-release dosage forms comprising zolpidem or a salt thereof
CA2648280C (fr) * 2006-04-03 2014-03-11 Isa Odidi Dispositif d'administration a liberation commandee comprenant un enrobage organosol
EP2024365A4 (fr) * 2006-06-05 2010-08-25 Auspex Pharmaceuticals Inc Préparation et utilité de composés d'imidazopyridine substitués ayant des effets hypnotiques
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008027557A2 (fr) * 2006-08-31 2008-03-06 Spherics, Inc. Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité
JP5275560B2 (ja) * 2006-10-24 2013-08-28 小林化工株式会社 酒石酸ゾルピデム含有素錠の製造方法
WO2008056139A2 (fr) * 2006-11-08 2008-05-15 Regen Therapeutics Plc Thérapie transdermique
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
MX2009003911A (es) * 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
WO2008070795A2 (fr) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Polythérapie utilisant de la doxépine à faible dose pour l'amélioration du sommeil
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
WO2008075372A1 (fr) * 2006-12-18 2008-06-26 Lupin Limited Formes pharmaceutiques à libération contrôlée de zolpidem
EP1938805A1 (fr) * 2006-12-22 2008-07-02 LEK Pharmaceuticals D.D. Comprimés monolithiques de zolpidem à libération prolongée
JP5467870B2 (ja) * 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
US20080254121A1 (en) * 2007-04-10 2008-10-16 Iomedix Sleep International Srl Multi-layer melatonin composition
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20090169618A1 (en) * 2007-12-26 2009-07-02 Limor Ari-Pardo Zolpidem pharmaceutical compositions
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
WO2009135680A1 (fr) 2008-05-09 2009-11-12 Grünenthal GmbH Procédé de préparation d'une formulation de poudre intermédiaire et d'une forme galénique solide finale en utilisant une étape de congélation par pulvérisation
EP2303025A4 (fr) * 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Procédés pour traiter des pathologies des graisses viscérales
TW201006473A (en) * 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
EP2260856A1 (fr) * 2009-05-12 2010-12-15 URSAPHARM Arzneimittel GmbH Composition de stimulation immunitaire comportant un extrait d'arona s en combinaison avec du sélénium et/ou du zinc
CN101884619B (zh) * 2009-05-15 2012-07-04 天津药物研究院 酒石酸唑吡坦缓释微丸及其制备方法
CN101574328B (zh) * 2009-06-18 2010-10-27 中国药科大学 一种唑吡坦盐的择时脉冲释药微丸
JP5628910B2 (ja) * 2009-07-07 2014-11-19 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５ｈ−ピロロ［３，４−ｂ］ピラジンの配合物
AU2010275755B2 (en) 2009-07-22 2014-04-24 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
CA2765971C (fr) 2009-07-22 2017-08-22 Gruenenthal Gmbh Forme galenique extrudee a chaud a liberation controlee
FR2949062B1 (fr) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
KR101010325B1 (ko) * 2009-12-17 2011-01-25 현대약품 주식회사 텔미사르탄 및 히드로클로로티아지드를 함유하는 약제학적 조성물
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
FR2962550B1 (fr) * 2010-07-06 2013-06-14 Ethypharm Sa Methode pour lutter contre la soumission chimique, utilisation d'agent colorant pour lutter contre la soumission chimique et composition pharmaceutique permettant la mise en oeuvre de la methode
FR2962331B1 (fr) * 2010-07-06 2020-04-24 Ethypharm Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre
CN103124559B (zh) 2010-08-04 2017-03-29 托马斯·朱利叶斯·波洛迪 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
EP2611426B1 (fr) 2010-09-02 2014-06-25 Grünenthal GmbH Forme pharmaceutique inviolable comportant un sel inorganique
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
NZ611868A (en) 2010-12-13 2015-11-27 Salix Pharmaceuticals Inc Gastric and colonic formulations and methods for making and using them
FR2968992B1 (fr) * 2010-12-16 2013-02-08 Sanofi Aventis Comprime pharmaceutique orodispersible a base de zolpidem
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
PH12015501410A1 (en) 2010-12-22 2015-09-07 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
EP2654733B1 (fr) 2010-12-23 2016-04-06 Purdue Pharma LP Formes pharmaceutiques solides à usage oral résistant à la contrefaçon
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
PT2736495T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente à adulteração proporcionando libertação imediata de fármaco
HUE034710T2 (hu) 2011-07-29 2018-02-28 Gruenenthal Gmbh Visszaéléssel szemben ellenálló, azonnali hatóanyagfelszabadulást biztosító tabletta
CN102552107B (zh) * 2012-01-12 2014-02-26 刘光权 含唑吡坦或其盐的双相释放制剂及其制备方法
WO2013127831A1 (fr) 2012-02-28 2013-09-06 Grünenthal GmbH Forme pharmaceutique inviolable comprenant un composé pharmacologiquement actif et un polymère anionique
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US20140377346A1 (en) * 2012-05-11 2014-12-25 Hanall Biopharma Co., Ltd. Bosentan controlled release oral preparation
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2013176774A1 (fr) 2012-05-25 2013-11-28 Arizona Board Of Regents Marqueurs de microbiome et thérapies pour troubles du spectre autistique
AU2013271336B2 (en) 2012-06-04 2017-11-30 Centre For Digestive Diseases Compositions and methods for treating Crohn's Disease and related conditions and infections
EP4104824A1 (fr) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition à utiliser dans une méthode de traitement de la surcharge pondérale et de l'obésité chez des patients présentant un risque cardiovasculaire élevé
RU2015106688A (ru) 2012-07-27 2016-09-20 Редхилл Байофарма Лтд. Препараты и способы получения препаратов для применения при опорожнении толстой кишки
EP3446685A1 (fr) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Libération auto-régulée d'ingrédient pharmaceutique actif
KR101840526B1 (ko) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 내변조성 제약 제제
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20160089363A1 (en) 2013-04-30 2016-03-31 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
EP3003279A1 (fr) 2013-05-29 2016-04-13 Grünenthal GmbH Forme pharmaceutique inviolable contenant une ou plusieurs particules
EP3003283A1 (fr) 2013-05-29 2016-04-13 Grünenthal GmbH Forme dosifiée inviolable à profil de libération bimodale
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
WO2015078891A1 (fr) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Préparation de composition pharmaceutique en poudre par cryo-broyage
SG10202004858TA (en) * 2014-02-06 2020-06-29 Lan Bo Chen Composition and method for aiding sleep
CA2943728C (fr) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Forme galenique solide de matrice biphasique a liberation immediate et dissuasive d'abus
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EP3148512A1 (fr) 2014-05-26 2017-04-05 Grünenthal GmbH Microparticules protégées contre une libération massive dans l'éthanol
EP3285745A1 (fr) 2015-04-24 2018-02-28 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
WO2016183577A1 (fr) 2015-05-14 2016-11-17 Crestovo Llc Compositions permettant la transplantation de flore fécale et méthodes de préparation et d'utilisation de ces dernières, et dispositifs pour leur administration
NZ737786A (en) 2015-05-22 2022-07-01 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
TR201801650T1 (tr) 2015-08-07 2018-03-21 Santa Farma Ilac Sanayii Anonim Sirketi Kontrollü salim propi̇veri̇n formülasyonlari
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
WO2017053327A1 (fr) 2015-09-24 2017-03-30 San Diego State University (Sdsu) Foundation , Dba San Diego State University Research Foundation Formulations de bactériophages antibactériennes et protectrices, procédés de fabrication et d'utilisation associés
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (fr) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions et méthodes pour traiter la sclérose en plaques et des troubles associés
WO2018071536A1 (fr) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions et procédés pour traiter la cholangite sclérosante primitive et des troubles associés
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018187467A1 (fr) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions et méthodes pour traiter la maladie de parkinson (pd) et des troubles associés
WO2018187464A1 (fr) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions et méthodes pour traiter la diverticulite et des troubles associés
EP3630190B1 (fr) 2017-05-26 2024-02-21 Finch Therapeutics Holdings LLC Compositions lyophilisées comprenant des agents thérapeutiques à base de microbes fécaux et leurs procédés de fabrication et d'utilisation
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019032573A1 (fr) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions et procédés pour le maintien et la restauration d'une barrière intestinale saine
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
CN112402389A (zh) * 2020-11-24 2021-02-26 常州欧法玛制药技术有限公司 一种唑吡坦双层渗透泵控释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US4397958A (en) * 1981-09-08 1983-08-09 The Foxboro Company Hydrocarbon analysis
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
FI894611A (fi) * 1988-09-30 1990-03-31 May & Baker Ltd Granulaera farmaceutiska preparat.
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives

Also Published As

Publication number Publication date
HUP0201915A3 (en) 2003-10-28
HK1037319A1 (en) 2002-02-08
KR20100130647A (ko) 2010-12-13
NO20012668L (no) 2001-08-06
DE69924283T2 (de) 2006-03-30
EP1135125A1 (fr) 2001-09-26
CN1334729A (zh) 2002-02-06
BR9915939A (pt) 2001-09-11
PL198396B1 (pl) 2008-06-30
CO5261492A1 (es) 2003-03-31
IL143146A0 (en) 2002-04-21
NZ511750A (en) 2003-10-31
JP4574857B2 (ja) 2010-11-04
SK7612001A3 (en) 2001-12-03
DE69924283T8 (de) 2008-05-21
AU771902B2 (en) 2004-04-08
ZA200104169B (en) 2002-05-22
CA2391983C (fr) 2010-11-09
CA2391983A1 (fr) 2000-06-15
KR101013272B1 (ko) 2011-02-08
US6514531B1 (en) 2003-02-04
AU2539900A (en) 2000-06-26
PT1135125E (pt) 2005-07-29
CZ20011969A3 (cs) 2001-09-12
EP1135125B1 (fr) 2005-03-16
JP2002531499A (ja) 2002-09-24
AR021535A1 (es) 2002-07-24
NO20012668D0 (no) 2001-05-30
SI1135125T1 (fr) 2005-08-31
EP1005863A1 (fr) 2000-06-07
PL348782A1 (en) 2002-06-17
IL143146A (en) 2007-09-20
KR20010080640A (ko) 2001-08-22
TR200101588T2 (tr) 2001-10-22
ES2239479T3 (es) 2005-09-16
CN1212838C (zh) 2005-08-03
JP2010070572A (ja) 2010-04-02
WO2000033835A1 (fr) 2000-06-15
ATE290861T1 (de) 2005-04-15
TW565448B (en) 2003-12-11
DE69924283D1 (de) 2005-04-21
HUP0201915A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
DK1135125T3 (da) Doseringsformer med reguleret frigivelse omfattende zolpidem eller et salt deraf
DK1600154T3 (da) Osmotisk doseringsform med forlænget frigivelse
NO20012915L (no) Ny farmasöytisk formulering
NO994992L (no) Farmasöytiske blandinger med appetitt hemmende aktivitet
DK1128831T3 (da) Farmaceutisk moxifloxacinpræparat
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
NO20003640D0 (no) Ny doseringsform
DK0758244T4 (da) Doseringsformer af azithromycin med styret frigivelse
ID23338A (id) Popok tarik sekali pakai
NO20011085L (no) Tablett med umiddelbar frigivningsvirkning
ID23299A (id) Formulasi-formulasi farmasi
ID26334A (id) Morfolinol yang aktif secara farmasi
DK1466615T3 (da) Farmaceutisk præparat
NO992692L (no) Nefadozon doseringsform
NO20005399D0 (no) Farmasøytisk preparat
NO20005890D0 (no) Antiangiogene peptidmedikamenter
ID23198A (id) Popok tarik sekali pakai
DK1056448T3 (da) Farmaceutiske kombinationer med tramadol
ATE218362T1 (de) Ifnnar/ifn komplex
ID27150A (id) Sediaan levotiroksin bahan farmasi
ID30032A (id) Formulasi farmasi
ID18027A (id) Garam amina
NO995853D0 (no) Nytt salt
SE9803952D0 (sv) Pharmaceutical formulation
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste